Ranbaxy gains on Prilosec generic

Ranbaxy Laboratories got a welcome dose of good news as its shares climbed more than 3 percent on the launch of its generic version of the acid reflux drug Prilosec in the U.S., under an agreement with AstraZeneca. Report

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.